Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesOhio Department of MedicaidOhio Medicaid Sickle Cell CGT Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentOhio Department of MedicaidPolicy N/A

    Sickle Cell Disease Cell and Gene Therapy (CGT) Access Policy

    Customize your policy alerts

    Sign up for all Ohio Department of Medicaid policy alerts

    Know when Ohio Department of Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Ohio Medicaid coverage and prior authorization for Casgevy and Lyfgenia in beneficiaries with sickle cell disease through the CMS Cell and Gene Therapy Access Model, provided through the Medicaid medical benefit except for dually eligible beneficiaries enrolled in MyCare Ohio.

    Policy Summary
    PayerOhio Department of Medicaid
    PolicySickle Cell Disease Cell and Gene Therapy (CGT) Access Policy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJanuary 1, 2026
    Next Review DateN/A
    Key ActionObtain Ohio Department of Medicaid prior authorization before initiating Casgevy or Lyfgenia treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered products
    ≥12 yearsMinimum age
    ≥2/yearCasgevy VOC threshold
    ≥4Lyfgenia VOE threshold
    12 monthsAuthorization length
    1Treatment courses per approval

    Coverage Criteria

    All-products criteria

    Covered when ALL of the following all-products criteria are met:

    All Products

    • Eligibility and enrollment

      • The beneficiary is currently enrolled in Ohio Medicaid Fee-for-Service or Managed Medicaid; has sickle cell disease confirmed by genetic testing; and is at least 12 years of age at the expected time of gene therapy administration.Age ≥12 years
    • Clinical and provider requirements

      • The beneficiary is clinically stable and fit for transplantation, and the medication is prescribed by or in consultation with a board-certified hematologist with sickle cell disease expertise.
    • Treatment center and registry requirements

    Policy Summary
    PayerOhio Department of Medicaid
    PolicySickle Cell Disease Cell and Gene Therapy (CGT) Access Policy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJanuary 1, 2026
    Next Review DateN/A
    Key ActionObtain Ohio Department of Medicaid prior authorization before initiating Casgevy or Lyfgenia treatment.
    SourceLink
    On This Page
    Coverage CriteriaKey Clinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsInitial Therapy by ProductRequired Prior TherapyTreatment Quantity LimitsAdministration Site Requirements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

  1. The administration facility is listed by the product manufacturer as an Authorized or Qualified Treatment Center, and the billing provider is a member of the CMS-designated patient registry for the CGT Model through the Center for International Blood & Marrow Transplant Research and agrees to participate in the CMS-specified study.
  2. Casgevy product-specific criteria

    Casgevy is covered when ALL of the following product-specific criteria are met, in addition to the all-products criteria:

    Casgevy

    • Hydroxyurea history: The beneficiary has prior use and failure of, or intolerance to, hydroxyurea.

      Determined according to health care professional judgment.

    • Recurrent vaso-occlusive crises: The beneficiary has experienced recurrent vaso-occlusive crises (VOCs).≥2 documented VOCs per year in the previous 24 months

      Based on provider attestation.

    Lyfgenia product-specific criteria

    Lyfgenia is covered when ALL of the following product-specific criteria are met, in addition to the all-products criteria:

    Lyfgenia

    • Hydroxyurea history: The beneficiary has prior use and failure of, or intolerance to, hydroxyurea.

      Determined according to health care professional judgment.

    • Treatment center: The eligible beneficiary's treatment center has a Sickle Cell Center.
    • VOE eligibility pathway

      • Chronic-transfusion pathway: The beneficiary is currently receiving chronic transfusion therapy for recurrent vaso-occlusive events (VOEs).
      • Recurrent-VOE pathway: The beneficiary has experienced four or more VOEs in the previous 24 months.≥4 VOEs in the previous 24 months

        Based on provider attestation.

    Coverage under this policy is provided through the Ohio Medicaid Fee-for-Service medical benefit, regardless of managed care enrollment status. Coverage under this policy excludes dually eligible beneficiaries enrolled in the MyCare Ohio program. The policy applies to Casgevy and Lyfgenia when the applicable coverage criteria are met.

    Key Clinical Thresholds

    Minimum age
    Minimum ageAt least 12 years
    TimingAt the expected time of gene therapy administration
    Applies toBeneficiaries receiving Casgevy or Lyfgenia under the all-products criteria
    Casgevy recurrent VOC threshold
    ProductCasgevy
    Required frequencyAt least 2 documented vaso-occlusive crises per year
    Measurement periodPrevious 24 months; based on provider attestation
    Lyfgenia recurrent VOE threshold
    ProductLyfgenia
    Required countAt least 4 vaso-occlusive events
    Measurement periodPrevious 24 months; based on provider attestation

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required Before Treatment

    Prior authorization is required before treatment. Providers must obtain Ohio Department of Medicaid prior authorization before initiating Casgevy (exagamglogene autotemcel) or Lyfgenia (lovotibeglogene autotemcel).

    Billing Rule

    Authorization Duration and Treatment Limit

    An authorization is valid for 12 months and approval is limited to one treatment course.

    • Authorization period: 12 months
    • Treatment limit: one treatment course
    Documentation Required

    Submit Clinical Documentation

    Submit all applicable clinical documentation and chart notes with the authorization request to support the member’s eligibility and medical-necessity criteria.

    • Include applicable documentation for all-products criteria.
    • Include applicable product-specific clinical documentation and chart notes.
    Documentation Required

    Provider Attestation Required

    The provider must attest to the applicable recurrent vaso-occlusive crisis or event criteria for the requested product.

    • Casgevy: Attest that the beneficiary experienced at least two documented VOCs per year during the previous 24 months.
    • Lyfgenia: Attest that the beneficiary is currently receiving chronic transfusion therapy for recurrent VOEs, or experienced four or more VOEs during the previous 24 months.
    Denial Risk

    No Retroactive Authorization

    Authorization must precede treatment. Ohio Department of Medicaid does not issue prior authorizations with a retroactive approval date.

    • Do not initiate Casgevy or Lyfgenia before authorization is obtained.
    • Retroactive approval dates are not issued.
    Denial Risk

    All Applicable Criteria Must Be Met

    Coverage requires that all applicable all-products criteria and product-specific criteria are met for the requested Casgevy or Lyfgenia treatment.

    • All-products criteria must be satisfied, including applicable clinical documentation and chart notes.
    • The requested product’s criteria must also be satisfied, including any required provider attestation.

    Policy Background

    This policy supports access to sickle cell disease cell and gene therapies through the Centers for Medicare and Medicaid Services Cell and Gene Therapy Access Model. It addresses coverage of Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel). Product selection is determined by the treating provider based on clinical criteria, FDA label indications, and the member’s individual circumstances.

    Key Definitions

    Recurrent vaso-occlusive crises
    TermRecurrent vaso-occlusive crises (VOCs)
    DefinitionAt least 2 documented VOCs per year
    Measurement periodPrevious 24 months, based on provider attestation
    Vaso-occlusive events
    TermVaso-occlusive events (VOEs)
    Eligibility pathwayLyfgenia eligibility may be established by 4 or more VOEs in the previous 24 months
    Alternative pathwayThe beneficiary may instead be currently receiving chronic transfusion therapy for recurrent VOEs
    Authorized/Qualified Treatment Center
    TermAuthorized/Qualified Treatment Center
    DefinitionAn administration facility listed by the product manufacturer as an Authorized or Qualified Treatment Center
    RequirementAdministration must occur at a manufacturer-listed facility

    Initial Therapy by Product

    Casgevy initial therapy

    For Casgevy initial therapy, ALL all-products criteria and ALL Casgevy-specific criteria must be met:

    • All-products criteria

      • The beneficiary is currently enrolled in Ohio Medicaid Fee-for-Service or Managed Medicaid; has sickle cell disease confirmed by genetic testing; is at least 12 years of age at the expected time of gene therapy administration; is clinically stable and fit for transplantation; the medication is prescribed by or in consultation with a board-certified hematologist with sickle cell disease expertise; the administration facility is listed by the product manufacturer as an Authorized or Qualified Treatment Center; and the billing provider is a member of the CMS-designated patient registry for the CGT Model through the Center for International Blood & Marrow Transplant Research and agrees to participate in the CMS-specified study.Age ≥12 years
    • Casgevy-specific criteria

      • The beneficiary has prior use and failure of, or intolerance to, hydroxyurea.

        Determined according to health care professional judgment.

      • The beneficiary has experienced recurrent vaso-occlusive crises (VOCs).≥2 documented VOCs per year in the previous 24 months

        Based on provider attestation.

    Lyfgenia initial therapy

    For Lyfgenia initial therapy, ALL all-products criteria and ALL Lyfgenia-specific criteria must be met; within the Lyfgenia criteria, either the chronic-transfusion pathway or the recurrent-VOE pathway must be satisfied:

    • All-products criteria

      • The beneficiary is currently enrolled in Ohio Medicaid Fee-for-Service or Managed Medicaid; has sickle cell disease confirmed by genetic testing; is at least 12 years of age at the expected time of gene therapy administration; is clinically stable and fit for transplantation; the medication is prescribed by or in consultation with a board-certified hematologist with sickle cell disease expertise; the administration facility is listed by the product manufacturer as an Authorized or Qualified Treatment Center; and the billing provider is a member of the CMS-designated patient registry for the CGT Model through the Center for International Blood & Marrow Transplant Research and agrees to participate in the CMS-specified study.Age ≥12 years
    • Lyfgenia-specific criteria

      • The beneficiary has prior use and failure of, or intolerance to, hydroxyurea.

        Determined according to health care professional judgment.

    Required Prior Therapy

    StepMedication requirementCoverage applicability
    1Prior use and failure of, or intolerance to, hydroxyurea, based on health care professional judgment.Required before Casgevy or Lyfgenia coverage

    Treatment Quantity Limits

    Quantity limit
    ProductsCasgevy or Lyfgenia
    Maximum quantityOne treatment course
    Authorization ruleApprovals are for one treatment course only

    Administration Site Requirements

    Note

    Use an Authorized or Qualified Treatment Center

    Administration must occur at a facility listed by the product manufacturer as an Authorized or Qualified Treatment Center.

  3. The eligible beneficiary's treatment center has a Sickle Cell Center.
  4. VOE eligibility pathway

    • Chronic-transfusion pathway: The beneficiary is currently receiving chronic transfusion therapy for recurrent vaso-occlusive events (VOEs).
    • Recurrent-VOE pathway: The beneficiary has experienced four or more VOEs in the previous 24 months.≥4 VOEs in the previous 24 months

      Based on provider attestation.